Effect of Esketamine intravenous controlled analgesia on postoperative pain and quality of recovery in cesarean section patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069125

Enrollment

Unknown

Registered

2023-03-07

Start date

2023-03-15

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean section

Interventions

sufentanil group:PCIA pump: Sufentanil 1.5mg/kg+ Nalbuphine 120mg+0.9%NS to 150ml

esketamine group:PCIA pump:Esketamine 1.5mg/kg+ Nalbuphine 120mg+0.9%NS to 150ml

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Cesarean section for single pregnant women with gestational age > 37 weeks (2) Anesthesia was combined with lumbar anesthesia and epidural anesthesia, and PCIA patients were required after surgery; (3) Maternal god Qing, can participate in research and investigation independently

Exclusion criteria

Exclusion criteria: (1) Age 40 years old (2) ASA grade III-IV (3) neurological or psychiatric disorders, (4) patients with prenatal depression (5) allergy to the drug of choice (6) patients with a history of chronic pain and patients with NSAIDs or opioid addiction (7) drug abuse, etc. (8) Pre-existing or gestational hypertension, preeclampsia, cardiovascular and cerebrovascular diseases; Fetal distress or abnormality; Multiple births; (9) Refuse to participate

Design outcomes

Primary

Measure	Time frame
Postoperative analgesic effect;First press time of analgesia pump;Press times within 48h;	—

Secondary

Measure	Time frame
Postoperative recovery quality;	—

Countries

China

Contacts

Public ContactYan Wenjun

Gansu Provincial Hospital

871523533@qq.com13893370700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026